newsfilter
← Latest News
Business Wire·

Magenta Therapeutics Focuses R&D and Operational Spending, Reduces Workforce and Extends Cash Runway

– Encouraging early data and progress in MGTA-117 Phase 1/2 targeted conditioning clinical trial – – Prioritization of portfolio spending allows for extension of cash runway into Q2 2024 – Magenta Therapeutics (NASDAQ:MGTA), a clinical-sta